I'm reaffirming my "Buy" rating on PayPal Holdings due to its strong recovery, undervaluation, and growth potential in the ...

Biotech M&A is heating up, and Mirum Pharmaceuticals stands out. Discover why analysts predict a 50% upside and long-term ...

LVMH's undervalued stock presents a buying opportunity with strong long-term growth potential. Click here to read an analysis ...

Summit Therapeutics (SMMT) stock received a new buy rating from Truist based on its deal-forming prospects in oncology. Read ...

Stocks are adjusting to yield curve normalization, not inflation fears. Job openings and ISM Services PMI rise suggest ...

The key pillar of my bull thesis is the company's ability to complete the $1.66 billion loan from the Department of Energy.

Fagron (ARSUF) has refocused its M&A strategy, regaining market trust despite recent FDA issues. Read why I think the stock ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

BUI gets positive ratings, DNP CEFs faces strong sell signals. Find out how a 12% distribution hike affects their current ...

GSK (GSK) stock is in focus as the company is nearing a $1B deal to acquire IDRx, a private biotech focused on a rare ...

Palantir Technologies Inc. stock is in a technical bear market, down 20% from its all-time high. Explore more details here.

The U.S. Treasury 10-year yield could trend toward 5% in 2025, supported by a combination of historical averages and a ...